Agilent Technologies, Inc. (NYSE:A) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday.

A number of other equities analysts also recently commented on the company. Barclays PLC restated a “buy” rating and issued a $67.00 price objective on shares of Agilent Technologies in a report on Wednesday, July 19th. Wells Fargo & Co upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $42.92 to $60.73 in a report on Wednesday, July 12th. Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a report on Monday, July 10th. Deutsche Bank AG restated a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a report on Thursday, June 22nd. Finally, BTIG Research raised their price objective on Agilent Technologies from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, May 24th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Agilent Technologies has a consensus rating of “Buy” and a consensus target price of $60.12.

Agilent Technologies (A) opened at 60.13 on Friday. The company has a market capitalization of $19.32 billion, a price-to-earnings ratio of 33.80 and a beta of 1.30. Agilent Technologies has a 52-week low of $42.92 and a 52-week high of $61.84. The firm has a 50 day moving average of $60.08 and a 200-day moving average of $55.15.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.10. The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the company earned $0.44 EPS. Equities analysts expect that Agilent Technologies will post $2.23 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Agilent Technologies, Inc. (NYSE:A) Upgraded to “Strong-Buy” at BidaskClub” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/06/agilent-technologies-inc-nysea-upgraded-to-strong-buy-at-bidaskclub.html.

In other news, Director James Cullen sold 15,482 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $59.04, for a total value of $914,057.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael R. Mcmullen sold 50,000 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $59.86, for a total value of $2,993,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,608 shares of company stock worth $6,737,509.

Several hedge funds and other institutional investors have recently modified their holdings of A. DnB Asset Management AS raised its position in shares of Agilent Technologies by 14.1% in the first quarter. DnB Asset Management AS now owns 40,449 shares of the medical research company’s stock valued at $2,139,000 after buying an additional 5,000 shares during the last quarter. Cullinan Associates Inc. raised its position in shares of Agilent Technologies by 26.9% in the first quarter. Cullinan Associates Inc. now owns 50,450 shares of the medical research company’s stock valued at $2,667,000 after buying an additional 10,700 shares during the last quarter. Cribstone Capital Management LLC raised its position in shares of Agilent Technologies by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 2,359 shares of the medical research company’s stock valued at $125,000 after buying an additional 54 shares during the last quarter. Fox Run Management L.L.C. raised its position in shares of Agilent Technologies by 111.0% in the first quarter. Fox Run Management L.L.C. now owns 21,947 shares of the medical research company’s stock valued at $1,160,000 after buying an additional 11,547 shares during the last quarter. Finally, Private Trust Co. NA raised its position in shares of Agilent Technologies by 2.1% in the first quarter. Private Trust Co. NA now owns 7,660 shares of the medical research company’s stock valued at $404,000 after buying an additional 161 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.